Skip to main content
SWOG logo

User account menu

  • Log in

Main navigation

  • About
    • History & Impact
    • Mission & Values
    • Leadership
    • Support SWOG
    • Join SWOG
    • Policies & Procedures
    • Careers
    • Contact Us
  • The SWOG Network
    • How We Work
    • Our Staff
    • Our Advocates
    • Our Partners
  • News & Events
    • News
    • SWOG Meetings
    • For Press
  • Clinical Trials
    • Biospecimen Submission
    • Biospecimen Access
    • Data Requests
    • Clinical Trials Search
    • Clinical Research Resources
    • Frequently Asked Questions
    • Publications
    • Institutions
    • Quality Assurance & Audits
    • Serious Adverse Events
    • Training Resources
    • ORP (CRA) Workbench
    • Protocol Workbench
  • Workbenches
    • ORP (CRA) Workbench
    • Protocol Workbench
    • VA Workbench
  • For Patients
    • Patient & Advocate Voices
    • Trials Open to Patients
    • About SWOG Cancer Trials
    • Joining a Trial

Section navigation

  • Recent Updates
    • 12/1/2025
    • 11/15/2025
    • 11/1/2025
    • 10/15/2025
    • 10/1/2025
    • 9/15/2025
    • 9/1/2025
    • 8/15/2025
    • 8/1/2025
    • 7/15/2025
    • 7/1/2025
    • 6/15/2025
    • All Updates

Breadcrumb

  1. SWOG
  2. Member Resources
  3. Trial & Business Updates
  4. iMATCH

Priority List iMATCH

S2101
II
Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
SWOG logo

Footer: Social Links

  • LinkedIn
  • Twitter
  • YouTube
Copyright © 2025

Footer

  • Disclaimer